Drugs that go through the FDA’s “breakthrough therapy” designation are accepted more swiftly, but are they safe? The recent incidence with pimavanserin specifies a need for a major reform that must occur in healthcare policy. Parkinson's Disease is a distressing neurological disorder. This deteriorating disease is noticeable by tremors, trouble moving, and indistinct speech, and can ultimately lead to dementia and depression.
Therefore, when the drug pimavanserin - which could efficiently treat the psychosis linked with Parkinson's was taken for Food and Drug Administration (FDA) trials, it was obvious that every person desired the medication available as speedily as possible. Due to this public pressure as well as pressure from the corporation that developed pimavanserin, the drug was hurried to the market without a complete FDA approval process. Despite high hopes that pimavanserin…
